--(BUSINESS WIRE)--Borean Pharma develops highly efficacious new generation protein compounds and antibody analogues using its proprietary technologies. The two main components of Borean’s technology platform are its CTLD library technology and a trimerisation technology. In addition, the Company has a broad set of supporting tools that cover key elements from research to product development, including the cost efficient E. coli based production of the final products. Borean has five product programmes, one of which has been acquired by Roche, targeting atherosclerosis, rheumatoid arthritis, Crohn’s disease and cancer and a number of discovery programmes. The Company believes that it can unleash the true potential of biopharmaceuticals by providing efficacious and cost-effective protein-based antibody analogues.
